- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Journal: The CardiAMP Cell Therapy for Heart Failure trial. (Pubmed Central) - Oct 30, 2023
The improved clinical outcomes demonstrated in CardiAMP are consistent with previous clinical trials including the Transendocardial Autologous Cells in Ischemic Heart Failure (TAC-HFT) trial, Prospective Randomized Trial of Direct Endomyocardial Implantation of Bone Marrow Cells for Treatment of Severe Coronary Artery Diseases (PROTECT-CAD), and REGENERATE-Ischemic Heart Disease trial. No abstract available
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Enrollment closed, Enrollment change: CardiAMP (clinicaltrials.gov) - Oct 10, 2023
P3, N=125, Active, not recruiting,
No abstract available Recruiting --> Active, not recruiting | N=250 --> 125
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Trial completion date, Trial primary completion date: CardiAMP (clinicaltrials.gov) - Jun 26, 2023
P3, N=250, Recruiting,
Recruiting --> Active, not recruiting | N=250 --> 125 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Trial primary completion date: CardiAMP (clinicaltrials.gov) - Aug 3, 2022
P3, N=250, Recruiting,
The ongoing randomized, controlled, blinded pivotal trial is designed to confirm these findings and evaluate key patient centric HFrEF outcomes. Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Trial completion date, Trial primary completion date: CardiAMP (clinicaltrials.gov) - Dec 15, 2021
P3, N=250, Recruiting,
Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Women With Heart Failure In The CardiAMP Cell Therapy Trial (Exhibit Hall: ePoster Hub) - Aug 9, 2021 - Abstract #HFSA2021HFSA_81;
P3
Females met the CPA criterion at a higher rate than males (75% vs 65%). All subjects who passed the CPA were successfully randomized into the cell therapy treatment or control arms per protocol.
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Trial completion date, Trial primary completion date: CardiAMP (clinicaltrials.gov) - Jul 16, 2020
P3, N=250, Recruiting,
All subjects who passed the CPA were successfully randomized into the cell therapy treatment or control arms per protocol. Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2020 --> Dec 2021
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Trial completion date, Trial primary completion date: CardiAMP (clinicaltrials.gov) - Jul 13, 2018
P3, N=250, Recruiting,
Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2020 --> Dec 2021 Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2020
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Enrollment open, Trial initiation date, Trial primary completion date: CardiAMP (clinicaltrials.gov) - Jan 5, 2017
P3, N=250, Recruiting,
Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2020 Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Dec 2016 | Trial primary completion date: Apr 2018 --> Dec 2019
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Trial initiation date: CardiAMP (clinicaltrials.gov) - Jul 20, 2016
P3, N=250, Not yet recruiting,
Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Dec 2016 | Trial primary completion date: Apr 2018 --> Dec 2019 Initiation date: Jan 2016 --> Aug 2016
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
Trial initiation date, Trial primary completion date: CardiAMP (clinicaltrials.gov) - Sep 24, 2015
P3, N=250, Not yet recruiting,
Initiation date: Jan 2016 --> Aug 2016 Initiation date: Aug 2015 --> Jan 2016 | Trial primary completion date: Nov 2017 --> Apr 2018
- |||||||||| CardiAMP Cell Therapy (BCDA-01) / BioCardia
New P3 trial: CardiAMP (clinicaltrials.gov) - May 8, 2015
P3, N=250, Not yet recruiting,
|
